MIRABEGRON AND UAS OUTCOMES DURING RIRS

THE EFFECT OF PREOPERATIVE MIRABEGRON ON URETERAL ACCESS SHEATH INSERTION SUCCESS AND URETERAL INJURY DURING RETROGRADE INTRARENAL SURGERY: A RETROSPECTIVE COMPARATIVE STUDY

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07566416

Enrollment

131

Registered

2026-05-05

Start date

2018-01-01

Completion date

2025-02-10

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stone, Retrograde Intrarenal Surgery (RIRS), Ureteral Access Sheath

Keywords

kidney stone, mirabegron, ureteral access sheath, retrograde intrarenal surgery

Brief summary

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Interventions

PROCEDURERetrograde intrarenal surgery

In our study, we evaluated the üreteral access sheath insertion rate in patients already using mirabegron for overactive bladder and scheduled for RIRS surgery for kidney stones. No additional intervention was performed beyond the routine surgical procedure.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients scheduled for RIRS due to kidney stones

Exclusion criteria

* preoperative ureteral stenting, * ureteral strictures, history of ureteral or bladder surgery, * anatomical abnormalities of the urinary tract, * active urinary tract infection, * pregnancy, * uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg), * use of medications affecting ureteral smooth muscle tone

Design outcomes

Primary

Measure	Time frame
Ureteral access sheath insertion rate	From January 2018 to October 2021

Secondary

Measure	Time frame
Ureteral injury rate	From January 2018 to October 2024

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026